Oncternal Therapeutics (ONCT) Expected to Announce Quarterly Earnings on Thursday

Oncternal Therapeutics (NASDAQ:ONCT) is anticipated to issue its quarterly earnings data after the market closes on Thursday, March 6th. Analysts expect the company to announce earnings of ($2.96) per share and revenue of $0.28 million for the quarter.

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $0.53 on Thursday. The stock has a market capitalization of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The business has a fifty day moving average price of $0.53 and a two-hundred day moving average price of $1.44. Oncternal Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $13.14.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Oncternal Therapeutics in a report on Sunday. They issued a “hold” rating for the company. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.